GNOM
Global X Genomics & Biotechnology ETF
The Global X Genomics & Biotechnology ETF seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 91.5 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Apr 05, 2019 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| MODERNA, INC. | 7.5 % |
| TWIST BIOSCIENCE CORP. | 6.4 % |
| 10X GENOMICS INC CLASS A | 5.5 % |
| GUARDANT HEALTH, INC. | 5.5 % |
| ILLUMINA INC | 4.8 % |
| NATERA INC | 4.6 % |
| GENSCRIPT BIOTECH CORPORATION | 3.8 % |
| VERTEX PHARMACEUTICALS INC | 3.6 % |
| BIO-TECHNE CORPORATION | 3.6 % |
| BIOMARIN PHARMACEUTICAL INC | 3.6 % |
Constituent Breakdown
| Number of holdings | 50 |
| Herfindahl-Hirschman Index | 337 |
| Wgt avg mkt cap (mns) | $45,412 |
| Large cap (>$10bn) | 47.0% |
| Mid cap ($2-10bn) | 44.0% |
| Small cap (<$2bn) | 9.0% |
| Developed mkts. | 96.3% |
| Emerging mkts. | 3.8% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 83.1 % |
 |
NETHERLANDS | 5.2 % |
 |
CHINA | 3.8 % |
 |
GERMANY | 3.1 % |
 |
SWITZERLAND | 3.0 % |
 |
BRITAIN | 1.2 % |
 |
SINGAPORE | 0.6 % |
Historical Performance
Standardized Performance (as of 08/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 41.7% | 75.3% | 19.0% | 12.8% | -7.8% | -- | -- | 0.6% |
| Dividend Yield | 0.1% | 2.4% | 0.9% | 0.6% | 0.3% | -- | -- | 0.2% |
| Total Returns | 41.9% | 77.8% | 19.8% | 13.3% | -7.5% | -- | -- | 0.8% | Ann. Volatility | 34.0% | 31.5% | 31.9% | 31.2% | 34.3% | -- | -- | 34.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.19 | 23% |
| MSCI EAFE | 1.01 | 25% |
| MSCI Emg Mkts | 0.53 | 18% |
Liquidity Measures
| Avg. volume (000) | 28 |
| ADV traded (mns) | $2 |
| Turnover | 2.0% |
| Avg. Bid/Ask (% of price) | 0.45% |
Technical Indicators
| 30d moving avg. (EMA) | $56.01 |
| Relative strength (RSI) | 60 |
| MACD/Signal | 1.29/0.99 |
| Bollinger Bands (Upper/Lower) | $60.34/$51.68 |
| Short interest (% of AUM) | 1.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. GNOM |
Expenses vs. GNOM |
ALTAR Score™ vs. GNOM |
|---|---|---|---|---|
| GNMX | Corgi Genomics & Precision Medicine ETF | 46.8% | -15 bp | -0.7% |
| ARKG | ARK Genomic Revolution ETF | 38.8% | +25 bp | +0.5% |
| HLTH | Tema Healthcare AI ETF | 35.5% | +25 bp | +2.9% |
| WDNA | WisdomTree BioRevolution Fund | 34.9% | -5 bp | +0.0% |
| HELX | Franklin Genomic Advancements ETF | 27.9% | 0 bp | +1.4% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 26.0% | +6 bp | +3.8% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 25.3% | +15 bp | +3.2% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 25.0% | +18 bp | +4.2% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 24.8% | -3 bp | +1.1% |
| BBH | VanEck Biotech ETF | 24.7% | -15 bp | +6.0% |
Risk and Returns: GNOM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/5/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-2.4%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 734 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. GNOM's ALTAR Score™ is approximately -2.6 standard
deviations above the category average. This places GNOM in the 1st percentile
among funds in the category.
Sell-Side Consensus
$63.97
PRICE TARGET
-0.5%
UPSIDE